MARKET

ARTL

ARTL

Artelo Biosciences Inc
NASDAQ
1.190
-0.050
-4.03%
Closed 16:00 02/27 EST
OPEN
1.250
PREV CLOSE
1.240
HIGH
1.275
LOW
1.165
VOLUME
26.09K
TURNOVER
--
52 WEEK HIGH
28.60
52 WEEK LOW
1.100
MARKET CAP
2.53M
P/E (TTM)
-0.0570
1D
5D
1M
3M
1Y
5Y
1D
Artelo Biosciences Q4 EPS $1.38 Beats $(1.57) Estimate
Benzinga · 3d ago
Artelo Biosciences Issues Business Update; Reports First-In-Human Phase 1 SAD Clinical Data Demonstrating Safety Profile, Predictable Pharmacokinetics, And Dosing Flexibility
Benzinga · 3d ago
Artelo Biosciences reports FY25 EPS ($12.52)
TipRanks · 3d ago
*Artelo Biosciences 2025 Loss/Shr $12.52 >ARTL
Dow Jones · 3d ago
Artelo (ARTL) FY 2025 net loss totals USD 12.9 million
Reuters · 3d ago
Press Release: Artelo Biosciences Provides -2-
Dow Jones · 3d ago
Press Release: Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results
Dow Jones · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 3d ago
More
About ARTL
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Webull offers Artelo Biosciences Inc stock information, including NASDAQ: ARTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARTL stock methods without spending real money on the virtual paper trading platform.